TickerTalks
Browse all tickers →
TickerTalks›$ASTH
ASASTH

Astrana Health, Inc.

$ASTH·$1.8B·Medical - Care Facilities·Healthcare
$35.13-3.4%YTD+38.7%1Y+21.2%
Price updated 13h ago·X counts updated 2d ago
ASASTH
$ASTHAstrana Health, Inc.
$35.13-3.41%25 posts0.9×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $ASTH on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

25X posts · last 7 days
Sep 11Sep 27
Chatter Meter
0.9×
QuietNormal · 1×Loud

How loud $ASTH's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $ASTH — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Broken storyWinding up for a moveAI verdict · as of 2026-09-28

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Astrana Health +43% YTD but three separate securities-fraud probes + a fresh 9/22 cybersecurity incident.

Astrana has an 81%-full-risk profitable business tangled up in class actions and a fresh cyber breach — the legal-litigation cycle is live.

  • Tape: +43.6% YTD, +30.5% t12m; 55% of 52w range, -4.1% vs 50-day, +12.4% vs 200-day.
  • Multiple investigations (Pomerantz, Lowey Dannenberg, AWKO Law) — securities-fraud + data-breach probes running.
  • 9/22: Item 1.05 cybersecurity incident disclosed — unauthorized access detected.
  • Q2 EPS $0.40 vs $0.336 (+19.1%); four straight beats; FY26 est $1.40 → FY27 $1.97 → FY28 $2.64 → FY29 $3.23 EPS.
  • 41.2x P/E TTM, 8.7x EV/EBITDA, 5.6% FCF yield, D/E 0.12 (clean).
  • Op margin 2.6%, gross margin 6.5%, ROIC 4.1% — thin-margin managed-care economics.
  • SA piece: '81% full-risk and profitable' — bull-case anchor.
  • No X sentiment sample.

Watch 11/5 print for the cyber-incident cost-quantification and any additional class-action lead-plaintiff developments.

What to watch: 11/5 earnings, cyber-incident cost quantification, class-action lead-plaintiff outcomes, and any full-risk contract updates.

On the calendar: 2026-11-05

sentiment missing

Read the AI verdict on $ASTH

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Physician-led healthcare management company operating value-based care networks and medical groups across California and other US markets.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Care Facilities sits in its cycle right now — and what that implies for $ASTH.

Medical - Care Facilities · Healthcare

Hospital system revenue recovery continues as elective procedure volumes normalize and commercial insurance mix improves; Medicaid rate cuts from state budget pressures and CMS site-neutral payment proposals are the margin headwinds. AI revenue cycle automation is reducing denials and accelerating reimbursement timelines, improving cash conversion for systems that adopt it.

What this means for $ASTH

Partial — Physician-led healthcare management company operating value-based care networks and medical groups across California and other US markets.

Top industry ETF

$IHFiShares U.S. Healthcare Providers ETF
+15.9%YTD
+13.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
41.2How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
4.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
2.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
5.6%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.4Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
5.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
6.5%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$0.40$0.34+19.1%
Q1 2026May 7, 2026$0.30$0.29+3.4%
Q4 2025Mar 2, 2026$0.12$0.15-20.0%
Q3 2025Nov 6, 2025$0.01$0.47-97.9%
Next earningsThu, Nov 5·consensus EPS $0.44

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$972.5M+48.5%0.0%3.5%$0.40$28.9M
Q1 FY26$965.1M+55.6%9.4%3.0%$0.30$64.1M
Q4 FY25$950.5M+42.9%8.3%1.9%$0.12$-6.0M
Q3 FY25$956.0M+99.7%8.5%2.0%$0.01$7.4M

Forward consensus

5-year forecast · up to 8 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$4.0B$4.0B – $4.0B$1.40$1.35 – $1.497
FY27$4.4B$4.2B – $4.6B$1.97$1.82 – $2.248
FY28$4.8B$4.7B – $5.2B$2.64$1.98 – $3.055
FY29$5.1B$5.0B – $5.3B$3.23$3.14 – $3.382
FY30$5.6B$5.4B – $5.7B$3.76$3.66 – $3.932

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.51%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-6.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+8.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 39.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.9% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.915-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 20 other (9 awards · 7 inkinds · 3 returns · 1 exempt) in window

See when $ASTH insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDSep 238-K — Item 7.01: Press release / Reg FD
8-KMaterial eventSep 238-K — Item 1.05
AI summary

Astrana Health (ASTH) disclosed a material cybersecurity incident (Item 1.05) detected on September 22, 2026, in which unauthorized access was identified and responded to by the company's security team; the company engaged a leading third-party digital forensics firm, notified law enforcement and state/federal regulators and payer partners, and implemented remedial measures including credential resets, remote access restrictions, clean-backup system restoration, and enhanced monitoring. The scope and nature of the incident remain under investigation. This is a material cybersecurity event with potential regulatory, operational, and reputational consequences given the sensitivity of healthcare data and payer relationships.

8-KPress release / Reg FDSep 158-K — Item 7.01: Press release / Reg FD
AI summary

Astrana Health (ASTH) updated its corporate investor presentation on September 15, 2026, for use at upcoming conferences and investor meetings, furnished as Exhibit 99.1 and not deemed filed. Routine Reg FD disclosure with no material new financial data in the filing body.

3New insider — initial holdingsAug 113
AI summary

Acuitas Therapeutics (ASTH) filed a Form 3 disclosing that the reporting officer holds 3,972 restricted shares of common stock, subject to vesting tied to continuous employment. Specific vesting schedule details are in the footnotes of the full form.

8-KPress release / Reg FDAug 68-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

ASTH filed an 8-K (Item 2.02) reporting its financial results, filed 2026-08-06. The actual financial figures are in the attached press release (Exhibit 99.1), not reproduced in the body excerpt. This is a material disclosure; investors should review the press release for beat/miss details and guidance.

8-KPress release / Reg FDJul 138-K — Item 7.01: Press release / Reg FD
AI summary

ASTH filed an 8-K (Item 7.01) for a Regulation FD disclosure. A presentation or investor communication is being furnished as an exhibit. Reg FD disclosures are furnished rather than filed and are not typically market-moving on their own, but may contain forward-looking statements or strategy updates.

8-KOfficer or director changeJul 18-K — Item 5.02: Officer or director change
AI summary

ASTH filed an 8-K (Item 5.02) reporting a director or officer change. not to u is involved in the change. The role noted: Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory . This is primarily an administrative disclosure; materiality depends on the seniority of the role and whether it reflects a strategic shift.

8-KOfficer or director changeJun 108-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

ASTH filed an 8-K (Item 5.02) reporting a director or officer change. not to u is involved in the change. The role noted: Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory . This is primarily an administrative disclosure; materiality depends on the seniority of the role and whether it reflects a strategic shift.

+ 10 other (3 8-Ks · 2 10-Qs · 2 proxys · 1 13G) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

ASTH Investors Have Opportunity to Join Astrana Health, Inc. Fraud Investigation with SBS Lawbusinesswire.com·21h agoPRIVACY ALERT: AWKO Law Investigating Astrana Health Data Breachbusinesswire.com·4d agoINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Astrana Health, Inc.- ASTHprnewswire.com·5d agoINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Astrana Health, Inc.- ASTHglobenewswire.com·7d agoLowey Dannenberg, P.C. is Investigating Astrana Health, Inc. (NASDAQ: ASTH) for Potential Violations of the Federal Securities Lawsglobenewswire.com·7d ago

More in Medical - Care Facilities

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$HIMS$THC$STLN$NUTX$CON$AVAH$NHC$PNTG
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport